Patents by Inventor Addison WRIGHT

Addison WRIGHT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TARGETING OF LPA
    Publication number: 20260152733
    Abstract: Provided herein are systems comprising Class 2, Type V CRISPR proteins and guide nucleic acids (gRNA) useful in the modification of a target nucleic acid of a lipoprotein (a) (LPA) gene. The systems are also useful for introduction into cells, for example eukaryotic cells. Also provided are methods for treating subjects having a LPA-related disease and methods for optimizing the encoding sequences.
    Type: Application
    Filed: September 29, 2025
    Publication date: June 4, 2026
    Inventors: Dena LEEMAN, Sarah DENNY, Sean HIGGINS, Brett T. STAAHL, Oleh KRUPA, Benjamin DEMAREE, Matthew HARMS, Benjamin OAKES, Addison WRIGHT
  • Compositions and methods for the targeting of PCSK9
    Patent number: 12594349
    Abstract: Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising a DNA binding domain such as a TALE, zinc finger or catalytically-dead CRISPR protein and guide nucleic acid (gRNA), which are useful in the repression of a proprotein convertase subtilisin/kexin Type 9 (PCSK9) gene. Also provided are methods of using such systems to repress transcription of PCSK9.
    Type: Grant
    Filed: November 21, 2023
    Date of Patent: April 7, 2026
    Assignee: Scribe Therapeutics Inc.
    Inventors: Jason Fernandes, Sean Higgins, Sarah Denny, Ross White, Emeric Jean Marius Charles, Addison Wright, Benjamin Demaree, Benjamin Oakes
  • Compositions and methods for the targeting of PCSK9
    Patent number: 12551573
    Abstract: Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising a DNA binding domain such as a TALE, zinc finger or catalytically-dead CRISPR protein and guide nucleic acid (gRNA), which are useful in the repression of a proprotein convertase subtilisin/kexin Type 9 (PCSK9) gene. Also provided are methods of using such systems to repress transcription of PCSK9.
    Type: Grant
    Filed: November 21, 2023
    Date of Patent: February 17, 2026
    Assignee: Scribe Therapeutics Inc.
    Inventors: Jason Fernandes, Sean Higgins, Sarah Denny, Ross White, Emeric Jean Marius Charles, Addison Wright, Benjamin Demaree, Benjamin Oakes
  • AAV VECTORS FOR GENE EDITING
    Publication number: 20250361525
    Abstract: Provided herein are recombinant adeno-associated virus (rAAV) compositions and methods for use of the rAAV encoding CasX proteins and guide ribonucleic acid (gRNA) sequences useful for nucleic acid sequence editing, and including transgene components. The rAAV may be delivered to cells to target a gene of interest.
    Type: Application
    Filed: June 7, 2023
    Publication date: November 27, 2025
    Inventors: Fred DEITER, Wenyuan ZHOU, Katherine BANEY, Isabel COLIN, Cécile FORTUNY, Addison WRIGHT, Brett T. STAAHL, Sean HIGGINS, Benjamin OAKES, Suraj MAKHIJA, Sarah DENNY, Manuel MOHR, Torrey BROWNELL, Angus SIDORE
  • ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS
    Publication number: 20250333767
    Abstract: Provided herein are systems of engineered Class 2, Type V nucleases and guide ribonucleic acid scaffolds useful for the editing of target nucleic acids. Also provided are methods of making and using such systems to modify nucleic acids.
    Type: Application
    Filed: June 1, 2023
    Publication date: October 30, 2025
    Inventors: Wenyuan ZHOU, Fred DEITER, Manuel MOHR, Benjamin OAKES, Sean HIGGINS, Sarah DENNY, Gayathri VIJAYAKUMAR, Trent GOMBERG, Addison WRIGHT
  • SELF-INACTIVATING VECTORS FOR GENE EDITING
    Publication number: 20240360474
    Abstract: Provided herein are compositions and methods for use of self-inactivating recombinant vectors (SIRV) encoding Class 2 Type V and guide ribonucleic acid (gRNA) sequences useful for nucleic acid sequence editing, and including self-inactivating components. The SIRV may be delivered to cells as part of an AAV vector to target a gene of interest.
    Type: Application
    Filed: March 18, 2024
    Publication date: October 31, 2024
    Inventors: Katherine BANEY, Isabel COLIN, Cécile FORTUNY, Sean HIGGINS, Suraj MAKHIJA, Brett T. STAAHL, Maroof ADIL, Benjamin OAKES, Addison WRIGHT, Angus SIDORE, Manuel MOHR, Sarah DENNY
  • COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9
    Publication number: 20240123089
    Abstract: Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising a DNA binding domain such as a TALE, zinc finger or catalytically-dead CRISPR protein and guide nucleic acid (gRNA), which are useful in the repression of a proprotein convertase subtilisin kexin Type 9 (PCSK9) gene. Also provided are methods of using such systems to repress transcription of PCSK9.
    Type: Application
    Filed: November 21, 2023
    Publication date: April 18, 2024
    Inventors: Jason FERNANDES, Sean HIGGINS, Sarah DENNY, Ross WHITE, Emeric Jean Marius CHARLES, Addison WRIGHT, Benjamin DEMAREE, Manuel MOHR, Wenyuan ZHOU, Benjamin OAKES
  • COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9
    Publication number: 20240124537
    Abstract: Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising a DNA binding domain such as a TALE, zinc finger or catalytically-dead CRISPR protein and guide nucleic acid (gRNA), which are useful in the repression of a proprotein convertase subtilisin/kexin Type 9 (PCSK9) gene. Also provided are methods of using such systems to repress transcription of PCSK9.
    Type: Application
    Filed: November 21, 2023
    Publication date: April 18, 2024
    Inventors: Jason FERNANDES, Sean HIGGINS, Sarah DENNY, Ross WHITE, Emeric Jean Marius CHARLES, Addison WRIGHT, Benjamin DEMAREE, Manuel MOHR, Wenyuan ZHOU, Benjamin OAKES
  • AAV VECTORS FOR GENE EDITING
    Publication number: 20240033377
    Abstract: Provided herein polynucleotides configured for incorporation into recombinant adeno-associated virus (AAV) vectors. The polynucleotides encode for CRISPR proteins, gRNA, and ancillary components of AAV vectors useful in the modification of target nucleic acids. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the target nucleic acid of a gene. Also provided are methods of using such AAV vectors to modify cells having such mutations.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 1, 2024
    Inventors: Manuel MOHR, Katherine BANEY, Angus SIDORE, Cécile FORTUNY, Maroof ADIL, Addison WRIGHT, Brett T. STAAHL, Sean HIGGINS, Benjamin OAKES, Suraj MAKHIJA, Sarah DENNY